Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort.
Magali RouyerEric FrançoisAntonio Sa CunhaAlain MonnereauEmmanuelle BignonJérémy JovéRégis LassalleCécile Droz-PerroteauNicholas MoorePernelle NoizeAnnie Fourrier-RéglatDenis SmithPublished in: British journal of clinical pharmacology (2020)
BRAF mutations were associated with markedly poorer outcomes in initially unresectable RASwt mCRC patients treated by cetuximab in first-line treatment.